These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

110 related articles for article (PubMed ID: 24769173)

  • 1. Anti-Parkinson effects of a selective alpha2C-adrenoceptor antagonist in the MPTP marmoset model.
    Philippens IH; Joosen MJ; Ahnaou A; Andres I; Drinkenburg WP
    Behav Brain Res; 2014 Aug; 269():81-6. PubMed ID: 24769173
    [TBL] [Abstract][Full Text] [Related]  

  • 2. L-DOPA-induced behavioral sensitization of motor activity in the MPTP-treated common marmoset as a Parkinson's disease model.
    Ando K; Inoue T; Itoh T
    Pharmacol Biochem Behav; 2014 Dec; 127():62-9. PubMed ID: 25449794
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Therapeutic effects of Delta9-THC and modafinil in a marmoset Parkinson model.
    van Vliet SA; Vanwersch RA; Jongsma MJ; Olivier B; Philippens IH
    Eur Neuropsychopharmacol; 2008 May; 18(5):383-9. PubMed ID: 18222654
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The adenosine A2A receptor antagonist, istradefylline enhances the anti-parkinsonian activity of low doses of dopamine agonists in MPTP-treated common marmosets.
    Uchida S; Soshiroda K; Okita E; Kawai-Uchida M; Mori A; Jenner P; Kanda T
    Eur J Pharmacol; 2015 Jan; 747():160-5. PubMed ID: 25499739
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The monoamine reuptake inhibitor BTS 74 398 fails to evoke established dyskinesia but does not synergise with levodopa in MPTP-treated primates.
    Hansard MJ; Smith LA; Jackson MJ; Cheetham SC; Jenner P
    Mov Disord; 2004 Jan; 19(1):15-21. PubMed ID: 14743355
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The novel adenosine A2a receptor antagonist ST1535 potentiates the effects of a threshold dose of L-DOPA in MPTP treated common marmosets.
    Rose S; Jackson MJ; Smith LA; Stockwell K; Johnson L; Carminati P; Jenner P
    Eur J Pharmacol; 2006 Sep; 546(1-3):82-7. PubMed ID: 16925991
    [TBL] [Abstract][Full Text] [Related]  

  • 7. An appraisal of the antiparkinsonian activity of piribedil in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-treated common marmosets.
    Smith L; De Salvia M; Jenner P; Marsden CD
    Mov Disord; 1996 Mar; 11(2):125-35. PubMed ID: 8684381
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Neurobehavioral protection by single dose l-deprenyl against MPTP-induced parkinsonism in common marmosets.
    Ando K; Maeda J; Inaji M; Okauchi T; Obayashi S; Higuchi M; Suhara T; Tanioka Y
    Psychopharmacology (Berl); 2008 Jan; 195(4):509-16. PubMed ID: 17879087
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The NR2B-selective NMDA receptor antagonist CP-101,606 exacerbates L-DOPA-induced dyskinesia and provides mild potentiation of anti-parkinsonian effects of L-DOPA in the MPTP-lesioned marmoset model of Parkinson's disease.
    Nash JE; Ravenscroft P; McGuire S; Crossman AR; Menniti FS; Brotchie JM
    Exp Neurol; 2004 Aug; 188(2):471-9. PubMed ID: 15246846
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antiparkinsonian actions of ifenprodil in the MPTP-lesioned marmoset model of Parkinson's disease.
    Nash JE; Fox SH; Henry B; Hill MP; Peggs D; McGuire S; Maneuf Y; Hille C; Brotchie JM; Crossman AR
    Exp Neurol; 2000 Sep; 165(1):136-42. PubMed ID: 10964492
    [TBL] [Abstract][Full Text] [Related]  

  • 11. De novo administration of ropinirole and bromocriptine induces less dyskinesia than L-dopa in the MPTP-treated marmoset.
    Pearce RK; Banerji T; Jenner P; Marsden CD
    Mov Disord; 1998 Mar; 13(2):234-41. PubMed ID: 9539335
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A novel adenosine A(1) and A(2A) receptor antagonist ASP5854 ameliorates motor impairment in MPTP-treated marmosets: comparison with existing anti-Parkinson's disease drugs.
    Mihara T; Iwashita A; Matsuoka N
    Behav Brain Res; 2008 Dec; 194(2):152-61. PubMed ID: 18657577
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Chronic L-DOPA administration induces dyskinesias in the 1-methyl-4- phenyl-1,2,3,6-tetrahydropyridine-treated common marmoset (Callithrix Jacchus).
    Pearce RK; Jackson M; Smith L; Jenner P; Marsden CD
    Mov Disord; 1995 Nov; 10(6):731-40. PubMed ID: 8749992
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antiparkinsonian action of a delta opioid agonist in rodent and primate models of Parkinson's disease.
    Hille CJ; Fox SH; Maneuf YP; Crossman AR; Brotchie JM
    Exp Neurol; 2001 Nov; 172(1):189-98. PubMed ID: 11681851
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antiparkinsonian activity of L-propyl-L-leucyl-glycinamide or melanocyte-inhibiting factor in MPTP-treated common marmosets.
    Katzenschlager R; Jackson MJ; Rose S; Stockwell K; Tayarani-Binazir KA; Zubair M; Smith LA; Jenner P; Lees AJ
    Mov Disord; 2007 Apr; 22(5):715-9. PubMed ID: 17373723
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Neuroprotective effects of modafinil in a marmoset Parkinson model: behavioral and neurochemical aspects.
    van Vliet SA; Vanwersch RA; Jongsma MJ; van der Gugten J; Olivier B; Philippens IH
    Behav Pharmacol; 2006 Sep; 17(5-6):453-62. PubMed ID: 16940766
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Atorvastatin improves cognitive, emotional and motor impairments induced by intranasal 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) administration in rats, an experimental model of Parkinson's disease.
    Castro AA; Wiemes BP; Matheus FC; Lapa FR; Viola GG; Santos AR; Tasca CI; Prediger RD
    Brain Res; 2013 Jun; 1513():103-16. PubMed ID: 23548600
    [TBL] [Abstract][Full Text] [Related]  

  • 18. D(1) dopamine receptor agonists are more effective in alleviating advanced than mild parkinsonism in 1-methyl-4-phenyl-1,2,3, 6-tetrahydropyridine-treated monkeys.
    Goulet M; Madras BK
    J Pharmacol Exp Ther; 2000 Feb; 292(2):714-24. PubMed ID: 10640310
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Recovery from experimental Parkinson's disease in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine hydrochloride treated marmoset with the melatonin analogue ML-23.
    Willis GL; Robertson AD
    Pharmacol Biochem Behav; 2005 Jan; 80(1):9-26. PubMed ID: 15652376
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Opicapone enhances the reversal of MPTP-induced Parkinson-like syndrome by levodopa in cynomolgus monkeys.
    Bonifácio MJ; Sousa F; Soares-da-Silva P
    Eur J Pharmacol; 2021 Feb; 892():173742. PubMed ID: 33220276
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.